BioMarin drug trial meets one of two primary endpoints By Investing.com

BioMarin's Phase 3 ENERGY 3 trial for BMN 401 met only 1 of 2 co-primary endpoints: plasma PPi rose significantly through week 52, but RGI-C scores did not improve, and secondary endpoints were also negative. The drug was generally well-tolerated with no new safety signals, but management said it is evaluating next steps and will present detailed results at an upcoming medical meeting. Shares were trading near their 52-week low at $50.76, with the stock down nearly 13% year to date.

Analysis

This is a classic binary-data disappointment, but the deeper issue is that the trial de-risks biology only halfway: biomarker engagement is real, yet the market now has evidence that PPi normalization alone is insufficient to move skeletal outcomes in a small pediatric population. That matters because it weakens the entire mechanistic bridge for BMN 401 and raises the bar for any follow-on label strategy, especially if payers view the program as a high-cost therapy without clear functional benefit.

The second-order read-through is more negative for rare-disease asset valuation frameworks than for BioMarin alone. Investors have been paying up for orphan franchises on the assumption that small trials can still translate into durable pricing power; this readout implies that endpoint design and natural-history noise can overwhelm even statistically clean pharmacology. If the company leans harder into commercialization, it may face a longer period of spend with little incremental NPV, while management credibility becomes more tied to the next pipeline disclosure.

The stock reaction may be overdone tactically if VOXZOGO continues to offset narrative damage, but structurally the market now has a catalyst to compress the multiple toward a single-asset orphan platform rather than a broad rare-disease compounder. The key timing window is the next 2-6 weeks around detailed presentation: if subgroup hints or longer-horizon functional trends are absent, this becomes a year-long sentiment overhang, not a one-day event. Conversely, any credible path to an expanded biomarker-based indication or a clean next-step development plan could stabilize the shares, but the burden of proof has shifted materially higher.

Key Decisions for Investors

• Short-term: buy BMRN puts or put spreads into the medical-meeting catalyst, targeting a 4-8 week horizon; risk/reward favors downside continuation if the company cannot surface an interpretable subgroup signal or alternate endpoint strategy.
• Medium-term: pair long GS / short BMRN only if you want sector-neutral exposure to the biotech beta reset; GS should benefit from lower execution risk and a cleaner analyst-framing backdrop while BMRN faces valuation compression.
• Add to a BMRN short on any bounce back toward the prior support zone over the next 1-3 weeks; use a tight stop above the post-event gap region because the stock can retrace mechanically if general market risk sentiment improves.
• For long-only holders, reduce BMRN exposure and rotate into names with clearer commercial visibility; the risk/reward has shifted from ‘pipeline optionality’ to ‘proof burden,’ which usually takes multiple quarters to repair.
• Watch for any announcement that BMN 401 will be re-scoped or partnered; that would be the first credible signal that internal NPV expectations have been cut, and it would likely catalyze another leg lower in the shares.